The first API summit of China API summit successfully concluded and won 1.84 million industry attention!

On October 23, the “API summit of the first China API summit” sponsored by pharmaceutical financial circle was successfully concluded in Suzhou, and 500 entrepreneurs attended the conference.

The scene was full of high-quality guests and dry goods sharing, which attracted the unanimous praise of the participants and attracted the attention of 1.84 million people in the industry. In the presence of all of you, pharmaceutical finance circle also released the latest strategic progress of three core industries, namely industrial park, fund and big data.

Wang Bo, the founder of the drug financial circle, said that the invisible circle economy has an impact on the industry. Now we know the industry information, and the experience is more and more transparent through the circle. The channels for gaining customers are changing.

In the past, the traditional Internet met with circle friends. The drug finance circle did not talk about integration, but talked about co construction. Through the circle and we media, the efficiency was high. The industry in the future is the ability to link.

The relationship between drug fusion circle and everyone is interdependent and ecological. I hope to integrate all of us through the integration of government, industry, University and research.

Real gold is not afraid of fire, people-oriented, common development, and then break the organizational barriers. For example, when suppliers and customers create value for us, they hope to give them equity and funds to participate in and break from the inside. Since the establishment of the drug fusion circle, we have a win-win idea and serve everyone.

Coping with centralized purchasing and global competition with competitiveness

Chairman Qiu Jiajun

The centralized purchase of drugs is a market-oriented behavior under the licensing economy. We should start from the mission of the pharmaceutical industry and adhere to the purpose of serving human health in our own way. As a special commodity, drugs are highly specialized competition. Only in large varieties and small varieties can we close the loop.

Second, from the professional technology, regional elements, cooperation platform and team building four business elements, to form a system or platform competitiveness, and finally said that Guobang pharmaceutical will respect the social division of labor, build a good industry platform;

integrity-based, do a good job in the industry chain; take time as the leading, complement the short innovation; complement each other, the strong priority, to be a supply ship for project cooperation.

Seize the historical opportunity and highlight the advantages of industrial chain

Deng Lili, Director / General Manager

At present, Tiandi Hengyi has completed the whole industrial chain layout with two wings and all terminals. Under the background of drug consistency evaluation and centralized purchase with volume, Tiandi Hengyi mainly adopts three products to cope with three modes, including candesartan axetil tablets for winning the bid for centralized purchase, atorvastatin calcium tablets for failing in centralized procurement, and improving new drugs for clinical promotion.

In the future, a single generic drug is not enough to meet the challenges for the generic pharmaceutical enterprises. Therefore, the ultimate goal of most pharmaceutical enterprises is to embark on the road of internationalization. In the future, under the accelerated pace of industry reform and development, and in the historical trend of leapfrog development of China’s pharmaceutical industry, we hope that tiantiantianhengyi will be a warrior who will carry on the past and open up the future, and live up to this era.

Experience of transforming fluorobenzene into American generic drug Anda

Dr. he Kuang, general manager of Yongtai Technology

General manager he introduced Yongtai technology’s upgrading road from characteristic fluorination leader to international pharmaceutical factory, which brought important experience sharing for pharmaceutical enterprises who want to transform.

Based on the characteristic fluorination technology, Yongtai has been building a vertical integrated industrial chain from intermediates to preparations from the layout of preparation market to the supplement of API industry. In the future development planning, it will also be based on the integration platform.

In the short term, we will continue to rely on the characteristic fluorine-containing intermediates and enzyme catalytic technology; in the medium term, we will form a technical reserve of pharmaceutical products with high technical barriers in the field of preparations, and in the future, we will realize the whole process of generic drug research and production from characteristic raw materials to high-end preparations through the high-tech barrier generic drug + innovative drug cdmo business.

We also cooperate with the first-class innovative pharmaceutical companies at home and abroad, and through the cooperation and intervention in the early clinical stage, we can realize the integrated commissioned production from API to preparation.

Wang Bo: Zhu Dong, under the new policy situation, what are your next thoughts and Thoughts on the integration of API preparation and cdmo?

Zhu fangmeng: at present, the topic of API preparation integration is very hot. The core reason lies in the price pressure and cost problems caused by centralized purchasing. Although the integrated layout of API preparations is very important, we do not agree that the company should complete the whole process from API to preparation.

We hope that enterprises can do their own professional part, and other parts can cooperate with strategic partners in depth. The essence of generic drugs and innovative drugs are different.

The core of generic drugs is currently through drug consistency evaluation, and the core of innovative drugs is clinical research and development and marketing. Finally, my point of view is to build a good core competitiveness of enterprises, strengthen cooperation with strategic partners, in order to face the problems brought by centralized purchasing.

Wang Bo: Mr. Bai Hua, former chairman of Haizheng Pharmaceutical Co., Ltd., would like to share with you some experience of Haizheng’s development from a chemical plant in front of us to a 10 billion enterprise?

Baihua: we are most concerned about the health of human beings all over the world. With the deepening of reform and opening up in China, people’s demand for drugs is higher and higher, and the pharmaceutical industry is developing faster and faster. I think the pharmaceutical industry is a sunrise industry that will never decline.

The first problem faced by enterprises is how to choose the target. There are too many duplicate products in the market. Enterprises should choose their own target market, and then determine the product field.

In addition to determining their own treatment areas and varieties, they also need to care about how to transfer to technological development. After all, in addition to the cost pressure, the other important problem is the technical competition.

Wang Bo: Mr. Li Dong, under the current policy situation, what’s your opinion on the next step of profit margin or industry change?

Li Xiaoxiang: our R & D of Anhui Xinxing implements the changes of China’s policy. I attended the meeting before and discussed the various drawbacks brought by consistency evaluation to Chinese pharmaceutical enterprises. I think we need to complete the bidding of purchasing with quantity under certain rationality.

At present, only when the raw materials and preparations are discussed together can we reasonably calculate the profits of the enterprise. Anhui Xinxing initially made a large variety with differentiation, but did not do generic drugs. We have a precise positioning and do not blindly seek big.

Wang Bo: Mr. Xue, how do you think about the development direction of the integration of raw materials and preparations and the establishment of generic drug projects?

Xue Yunli: there are thousands of roads to success, but they have never been smooth. The early green leaves also met some challenges. We are a preparation enterprise. We should be the strongest in our own field, make equipment according to the nature of the process, and then develop products with suppliers.

We have our own characteristics, so it is difficult for others to imitate. We hope that the relationship with our partners will be symbiotic, which is our idea of internationalization. In this field, we must stick to it, even if we encounter difficulties. Finally, we can find our own advantages and create our own advantages.

Wang Bo: Mr. Qiu, under the current situation of centralized procurement, facing the competition at home and abroad, how to position and think about Guobang pharmaceutical industry in the next step?

Qiu Jiajun: under the background of centralized purchasing, the core of the mode of API preparation integration + cdmo is still technology and cost. The IPO in the future will also provide us with capital. We will build a good sales channel in advance to cope with the current situation.

The varieties of Guobang pharmaceutical industry are relatively concentrated, and they also hope to achieve serialization for the future drugs. Another regional problem: at present, the plant is located in the Yangtze River Delta region, and the second place is located in Weifang, Shandong Province, which is located in the Bohai economic circle. In order to create a relatively centralized platform, it can become our supply ship.

Wang Bo: Mr. Meng, please share the difficulties and experiences encountered by Chinese enterprises in the process of team running in and project operation after the acquisition of overseas enterprises by Chinese enterprises, and what is the future international strategic layout of epic pharma and puke pharmaceutical in the United States?

Meng Xiaofeng: at the beginning of internationalization, I hope to learn from overseas GMP, and the ultimate goal is to sell our generic drugs internationally. At present, we have a team of more than 400 people overseas. In addition to a certain running in period in terms of cultural concepts and management methods, other aspects are relatively smooth. At present, we are determined to go to the U.S.

market and continue to expand our market share. In the aspect of API preparation integration, the current consideration is the cost control of API, especially in India. The cost control of some of their companies is beyond our imagination, and the integration of their raw materials and preparations is quite perfect.

Second, the optimization of costs is cyclical and can not be relaxed. I hope that entrepreneurs can break their barriers and cooperate with each other to keep warm in the international market.

Wang Bo: what is general manager Wei’s industrial layout of Zhongrun pharmaceutical?

Wei Linhua: we are still small and medium-sized enterprises in the process of development. What enterprises expect most is to survive for a long time. It is important to seize their own advantages. For our own enterprises, we hope to go to the R & D end in the future. Now mainly do preparations, hope to do some innovative things in the future.

For sale, buy peptides, purchase peptides, and buy peptides online, you can find the Chinese peptide company:

Shengnuo Biotechnology is a high-tech China polypeptide manufacturers,who has over 19 years experience for the biotechnology .Our Products involve peptide raw materials,polypeptide drug.

Our 0 defect has passed the FDA certification, and has become the first-class professional polypeptide drug and product development and large-scale production and export industry in China .

Our service scope：peptide synthesis、peptide hormones、peptide medicine、beauty peptide、peptide medicine product、peptide technology transfer、peptide technology service、peptide large-scale production、export of peptide

Thymopentin for Injection、 Thymalfasin for Injection 、 Bivalirudin 、Bulk Drug、 Liraglutide ……